Who Paid My Doc
Frederick Gibson
Procedural Dermatology Jamaica Plain, MA Medical Doctor
NPI 1629604483 CMS profile 9926696
1153 Centre St, Jamaica Plain, MA 02130
General payments
$121
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Frederick Gibson of Jamaica Plain, MA is reported in the CMS Open Payments database as having received $121 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 14th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $121 | 1 |
Beside peers
- Frederick Gibson
- Procedural Dermatology median
- Middle half of Procedural Dermatology
- National median
In program year 2025, general payments to Frederick Gibson were reported at $0. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.
Show as a table
| Year | Frederick Gibson | Procedural Dermatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $454 | $152–$1,260 | $163 |
| 2020 | $0 | $243 | $90–$835 | $114 |
| 2021 | $0 | $337 | $102–$1,128 | $132 |
| 2022 | $0 | $443 | $119–$1,654 | $149 |
| 2023 | $0 | $583 | $137–$1,838 | $160 |
| 2024 | $121 | $611 | $132–$1,835 | $164 |
| 2025 | $0 | $592 | $144–$1,778 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
168
Drug cost
$79,097
Branded share of claims
16.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 13 | $75,613 | |
| Ketoconazole | Generic | 88 | $1,615 | |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | Brand | 15 | $736 | |
| Clindamycin Phosphate | Generic | 13 | $443 | |
| Triamcinolone Acetonide | Generic | 26 | $432 | |
| Doxycycline Monohydrate | Generic | 13 | $258 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Procedural Dermatology in Massachusetts
Karen Carreiro
Procedural Dermatology · Fall River, MA
Nellie Konnikov
Procedural Dermatology · Boston, MA
Jay Goldstein
Procedural Dermatology · Natick, MA
Catherine Digiorgio
Procedural Dermatology · Boston, MA
Dennis Porto
Procedural Dermatology · Milford, MA
Frank Vleugels
Procedural Dermatology · Boston, MA
Related records
Procedural Dermatology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Procedural Dermatology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.